BIIB

Biogen Inc.

Price

$203.89

return (12m)

59.29%

p/e

36.48

p/bv

1.62

DIVIDEND YIELD

0.00%

BIIB price

Biogen

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment BIIB

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

0.53%

3 months

-0.31%

1 year

59.29%

2 years

0.94%

5 years

-40.43%

10 years

-34.94%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals BIIB

Valuation

P/E

36.48

Sector -4.25

Industry -4.25

P/BV

1.62

Sector 2.05

Industry 2.05

P/Revenue (PSR)

3.04

Sector -4.32

Industry -4.32

EV/EBITDA

80.86

Sector -223.70

Industry -223.70

EV/EBIT

169.77

Sector -658.37

Industry -658.37

P/EBITDA

14.23

Sector -4.42

Industry -4.42

P/EBIT

23.49

Sector -4.65

Industry -4.65

P/Total Assets

0.95

Sector 1.48

Industry 1.48

P/Net Current Assets

-5.13

Sector -11.90

Industry -11.90

P/Working Capital

8.98

Sector -12.45

Industry -12.45

EPS

5.64

Sector -2.19

Industry -2.19

BVPS

127.35

Sector 1.87

Industry 1.87

Efficiency

Gross Margin

73.99%

Sector 36.35%

Industry 36.35%

EBITDA Margin

16.48%

Sector -16,780.87%

Industry -16,780.87%

EBIT Margin

7.85%

Sector -4,293,432.86%

Industry -4,293,432.86%

Operating Margin

19.29%

Sector -38.73%

Industry -38.73%

Net Profit Margins

8.32%

Sector -39.98%

Industry -39.98%

Asset Turnover

0.09

Sector 0.03

Industry 0.03

Profitability

ROE

4.43%

Sector -67.22%

Industry -67.22%

ROA

2.60%

Sector -66.45%

Industry -66.45%

ROIC

5.64%

Sector -2,064.28%

Industry -2,064.28%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

0.00%

Sector -

Industry -

Debt

Current Ratio

1.87

Sector 2.89

Industry 2.89

Net Debt / EBITDA

13.32

Sector -13,956,095.71

Industry -13,956,095.71

Net Debt / EBIT

27.97

Sector -7.72

Industry -7.72

Net Debt / Equity

0.32

Sector -1.09

Industry -1.09

Gross Debt / Equity

0.39

Sector -0.07

Industry -0.07

Equity/Assets

0.59

Sector 0.41

Industry 0.41

Liabilities/Assets

0.41

Sector 0.40

Industry 0.40

Growth

5Y Revenue CAGR

-1.80%

Sector -

Industry -

5Y Earnings CAGR

-11.71%

Sector -

Industry -

FAIR VALUE OF Biogen ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$203.89

Fair Value

$127.12

Upside Return potential.

-37.65%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Fundamentals BIIB

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
BIIB Biogen Inc.	$203.89	56.03%	0.00%	36.48	1.62	4.43%	8.32%
JNJ Johnson & Johnson	$259.80	54.01%	2.05%	29.23	7.24	24.76%	21.48%
PFE Pfizer Inc.	$26.62	17.93%	6.61%	34.22	1.73	5.07%	6.80%
ABBV AbbVie Inc.	$249.93	30.95%	2.72%	69.54	-74.01	-106.44%	9.81%
NVO Novo Nordisk A/S	$47.17	0.58%	4.00%	11.36	6.03	53.11%	35.32%
MRK Merck & Co. Inc.	$130.42	68.08%	2.63%	99.31	0.00	-%	4.77%
AZN AstraZeneca PLC	$158.75	7.88%	2.01%	23.71	4.92	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$63.61	45.00%	3.91%	14.14	5.88	41.59%	18.87%
ZTS Zoetis Inc.	$75.35	-47.71%	2.81%	11.73	9.74	83.10%	27.49%
REGN Regeneron Pharmaceuticals Inc.	$797.00	43.99%	0.47%	18.55	2.53	13.65%	27.86%
AMGN Amgen Inc.	$414.30	49.01%	2.43%	24.89	18.62	74.80%	22.95%
HALO Halozyme Therapeutics Inc.	$102.62	63.15%	0.00%	28.46	82.01	288.14%	24.86%
MCK McKesson Corporation	$901.77	35.57%	0.37%	22.83	-80.58	-352.96%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$529.65	44.50%	0.00%	28.28	6.15	21.76%	35.00%
CAH Cardinal Health Inc.	$240.26	54.24%	0.86%	36.08	-21.00	-58.20%	0.62%
HRMY Harmony Biosciences Holdings Inc.	$39.52	15.59%	0.00%	12.41	2.25	18.14%	18.89%
MEDP Medpace Holdings Inc.	$605.50	39.40%	0.00%	33.22	37.63	113.29%	17.67%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

BIIB Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Biogen

Biogen Inc.

Average Investor10 user rating

4.0 (16 people)

United States

48 years

Founded: 1978

1991

Time since IPO - 35 years

9.100

Employees

Biogen Inc. (United States) is listed on the Nasdaq and has a market capitalization of $30.45 billion, with shareholders equity totaling $18.85 billion.

The company employs approximately 9.100 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Biogen Inc. reported $10.03 billion in revenue, generating net income of $834.60 million.

Key financial metrics include a P/E ratio of 36.48, a price-to-book (P/B) ratio of 1.62, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker BIIB.

Market cap

$30.45 billion

Net worth

$18.85 billion

$18,848,000,000.00

Assets

$32.09 billion

$32,086,600,000.00

Total Shares Outstanding

148.00 million

148,000,000

Average Daily Trading Volume

$1.26 million

$1,262,898.00

Sector

Health Care

Industry

Biotechnology

BIIB

revenue by Business Segment Biogen

Revenue by Region Biogen

BIIB revenue and profits

Financial Results BIIB

DRAG THE FRAME TO SEE MORE DATA

BIIB cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$901.77 37,54% (12M)

P/E

22.83

0.37%

ROE

-352.96%

P/BV

-80.58

CAH - Cardinal Health

$240.26 65,95% (12M)

P/E

36.08

0.86%

ROE

-58.20%

P/BV

-21.00

JNJ - Johnson & Johnson

$259.80 54,94% (12M)

P/E

29.23

2.05%

ROE

24.76%

P/BV

7.24

ABBV - AbbVie

$249.93 30,95% (12M)

P/E

69.54

2.72%

ROE

-106.44%

P/BV

-74.01

MRK - Merck & Co.

$130.42 68,90% (12M)

P/E

99.31

2.63%

ROE

P/BV

0.00

AZN - AstraZeneca

$158.75 4,28% (12M)

P/E

23.71

2.01%

ROE

20.74%

P/BV

4.92

PFE - Pfizer

$26.62 17,59% (12M)

P/E

34.22

6.61%

ROE

5.07%

P/BV

1.73

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$901.77 37,54% (12 M)

P/L

22.83

0.37%

ROE

-352.96%

P/VP

-80.58

CAH - Cardinal Health

$240.26 65,95% (12 M)

P/L

36.08

0.86%

ROE

-58.20%

P/VP

-21.00

JNJ - Johnson & Johnson

$259.80 54,94% (12 M)

P/L

29.23

2.05%

ROE

24.76%

P/VP

7.24

ABBV - AbbVie

$249.93 30,95% (12 M)

P/L

69.54

2.72%

ROE

-106.44%

P/VP

-74.01

MRK - Merck & Co.

$130.42 68,90% (12 M)

P/L

99.31

2.63%

ROE

P/VP

0.00

AZN - AstraZeneca

$158.75 4,28% (12 M)

P/L

23.71

2.01%

ROE

20.74%

P/VP

4.92

PFE - Pfizer

$26.62 17,59% (12 M)

P/L

34.22

6.61%

ROE

5.07%

P/VP

1.73

Frequently Asked Questions

What is the price of Biogen (BIIB) today?

A cotação de Biogen (BIIB) hoje está em US$ 203.89, com uma variação de 59.29% em relação ao último ano. A cotação de Biogen (BIIB) iniciou o ano negociando na casa dos US$ 175.99 e hoje está em US$ 203.89. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Biogen (BIIB) e dados de ações do Ibovespa e mercados internacionais.

Quando Biogen (BIIB) paga dividendos?

Biogen (BIIB) não distribuiu dividendos no último ano.

Is Biogen (BIIB) a good investment?

Atualmente, Biogen (BIIB) está cotada a US$ 203.89, com um P/L de 36.48, representando um desvio de 2,308% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 59.29 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 59.29%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Biogen (BIIB) stock?

Investir em ações de Biogen (BIIB) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Biogen (BIIB) yield today?

A rentabilidade de Biogen (BIIB) foi de 0.53% no último mês, 59.29% no último ano e -40.43% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Biogen (BIIB) hoje, o investimento total seria de US$ 20,389.00, com base na cotação atual de US$ 203.89.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 32,477.64
Em 5 anos: US$ 12,145.73
Em 10 anos: US$ 13,265.08

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

BIIB

Biogen Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment BIIB

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

Graham's Fair Value

COMPARING BIIB WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Biogen

Biogen Inc.

United States

48 years

1991

9.100

PROFIT X PRICE BIIB

Financial Results BIIB

BIIB cash flow

Asset, Revenue and Profit Growth - BIIB

BIIB balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions